Abstract
Patients vary considerably in their response to drug therapy. A drug that proves to be pharmacologically effective in some patients at a given dose may be ineffective or even toxic in others. The interindividual variability in drug response represents a major challenge in drug therapy, particularly for drugs with narrow therapeutic index. The intensity and duration of a drug action are determined not only by pharmacokinetic processes, but also by pharmacodynamic processes. Therefore, the variability in drug response is a result of the variability in either pharmacokinetic or pharmacodynamic processes, or a combination of both. The purpose of this paper is to review the sources that contribute to pharmacokinetic and pharmacodynamic variability. Although the main focus will be on the genetic variability, the impact of environmental factors on drug response will also be discussed. Finally, the application and limitation of the concept of personalized medicine will be briefly discussed.
Keywords: Butyrylcholinesterase, N-Acetyltransferase polymorphism, CYP 2D6, UDP-Glucuronosyltransferases, Drug Transporters
Current Drug Metabolism
Title: Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Volume: 8 Issue: 2
Author(s): Jiunn H. Lin
Affiliation:
Keywords: Butyrylcholinesterase, N-Acetyltransferase polymorphism, CYP 2D6, UDP-Glucuronosyltransferases, Drug Transporters
Abstract: Patients vary considerably in their response to drug therapy. A drug that proves to be pharmacologically effective in some patients at a given dose may be ineffective or even toxic in others. The interindividual variability in drug response represents a major challenge in drug therapy, particularly for drugs with narrow therapeutic index. The intensity and duration of a drug action are determined not only by pharmacokinetic processes, but also by pharmacodynamic processes. Therefore, the variability in drug response is a result of the variability in either pharmacokinetic or pharmacodynamic processes, or a combination of both. The purpose of this paper is to review the sources that contribute to pharmacokinetic and pharmacodynamic variability. Although the main focus will be on the genetic variability, the impact of environmental factors on drug response will also be discussed. Finally, the application and limitation of the concept of personalized medicine will be briefly discussed.
Export Options
About this article
Cite this article as:
Lin H. Jiunn, Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy, Current Drug Metabolism 2007; 8 (2) . https://dx.doi.org/10.2174/138920007779816002
DOI https://dx.doi.org/10.2174/138920007779816002 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology PPARs and Diabetes-Associated Atherosclerosis
Current Pharmaceutical Design Vascular, Oxidative, and Synaptosomal Abnormalities During Aging and the Progression of Type 2 Diabetes
Current Neurovascular Research Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics Non-Invasive Assessment of Atherosclerosis Risk
Current Drug Targets - Cardiovascular & Hematological Disorders Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?
Current Medicinal Chemistry The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Current Rheumatology Reviews Current Status of Computer-Aided Drug Design for Type 2 Diabetes
Current Computer-Aided Drug Design Torasemide for the Treatment of Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets The Challenges of RSV Vaccines. Where do we Stand?
Recent Patents on Anti-Infective Drug Discovery Blood Biomarkers in Cardioembolic Stroke
Current Cardiology Reviews Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design What Changes we may Expect in 2010 Hypertension Diagnosis and Management: Insights from the European Update Document
Current Vascular Pharmacology Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches
Current Medicinal Chemistry Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews Tobacco Smoking and Association between Betel Nut Chewing and Metabolic Abnormalities Among Military Males: The CHIEF Study
Endocrine, Metabolic & Immune Disorders - Drug Targets